GW Pharmaceuticals PLC- (NASDAQ:GWPH)‘s stock had its “buy” rating reiterated by research analysts at Morgan Stanley in a research report issued to clients and investors on Tuesday, TipRanks reports.

A number of other equities analysts also recently weighed in on the stock. Oppenheimer began coverage on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, December 11th. They set a “hold” rating and a $142.00 price target on the stock. BidaskClub downgraded shares of GW Pharmaceuticals PLC- from a “sell” rating to a “strong sell” rating in a research note on Friday, December 28th. JPMorgan Chase & Co. began coverage on shares of GW Pharmaceuticals PLC- in a research note on Wednesday, January 2nd. They set an “overweight” rating and a $134.00 price target on the stock. ValuEngine downgraded shares of GW Pharmaceuticals PLC- from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 2nd. Finally, AltaCorp Capital reaffirmed an “outperform” rating on shares of GW Pharmaceuticals PLC- in a research note on Monday, January 7th. Two investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. GW Pharmaceuticals PLC- currently has a consensus rating of “Buy” and a consensus target price of $180.73.

Shares of GWPH opened at $172.32 on Tuesday. The company has a current ratio of 6.66, a quick ratio of 6.34 and a debt-to-equity ratio of 0.01. The company has a market cap of $5.10 billion, a P/E ratio of -16.32 and a beta of 2.80. GW Pharmaceuticals PLC- has a 1 year low of $90.14 and a 1 year high of $182.23.

In other news, insider Volker Knappertz sold 4,140 shares of the stock in a transaction on Tuesday, February 26th. The shares were sold at an average price of $12.46, for a total value of $51,584.40. Following the completion of the sale, the insider now owns 9,612 shares of the company’s stock, valued at $119,765.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Justin D. Gover sold 23,400 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $14.01, for a total transaction of $327,834.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,895,496 shares of company stock worth $27,538,565. 5.50% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in the company. Belpointe Asset Management LLC increased its position in shares of GW Pharmaceuticals PLC- by 6.2% in the fourth quarter. Belpointe Asset Management LLC now owns 1,463 shares of the biopharmaceutical company’s stock worth $142,000 after acquiring an additional 85 shares in the last quarter. Advisory Services Network LLC increased its position in shares of GW Pharmaceuticals PLC- by 23.1% in the fourth quarter. Advisory Services Network LLC now owns 511 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 96 shares in the last quarter. Horrell Capital Management Inc. increased its position in shares of GW Pharmaceuticals PLC- by 33.3% in the fourth quarter. Horrell Capital Management Inc. now owns 400 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 100 shares in the last quarter. Edmond DE Rothschild Holding S.A. increased its position in shares of GW Pharmaceuticals PLC- by 16.7% in the fourth quarter. Edmond DE Rothschild Holding S.A. now owns 700 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 100 shares in the last quarter. Finally, Resources Investment Advisors Inc. increased its position in shares of GW Pharmaceuticals PLC- by 51.9% in the fourth quarter. Resources Investment Advisors Inc. now owns 366 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 125 shares in the last quarter. 79.42% of the stock is owned by institutional investors.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Further Reading: Do stock splits help investors?

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.